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In this issue of Immunity, Laurence et al. (2007) examined the effects of interleukin-2 on differentiation
of the T helper 17 (Th17) cells and found that this essential growth factor for all other T cell subsets
blocks the development of Th17 T cells.Interleukin 2 (IL-2) is one of the first cy-
tokines identified, and it is firmly estab-
lished as an important growth factor
supporting a plethora of T cell func-
tions. In vitro, IL-2 is obligatory for
the growth of T helper 1 (Th1) or Th2
as well as CD8+ T cells. This function
of IL-2 is less obvious in vivo because
IL-2-deficientmice suffer fromahyper-
proliferative disorder. Nevertheless,
IL-2 is essential for the acquisition of
effector functions mediated by, for
instance, interferon- g (IFN-g) or per-
forin. Thus, immunologists tend to add
IL-2 into their T cell cultures on impulse
and it is hardly even mentioned in the
methods section of a paper anymore.
However, as shown by Laurence et al.
(2007) in this issue of Immunity, Th17
T cell differentiation is different and
strongly discouraged by the presence
of IL-2.
Not only does the Th17 cell subset
develop in response to the seemingly
paradoxical combination of TGF-b,
which is generally considered an
anti-inflammatory cytokine, and IL-6,
a proinflammatory cytokine (Bettelli
et al., 2006; Mangan et al., 2006; Veld-
hoen et al., 2006), but as shown by
Laurence et al. (2007), Th17 differenti-
ation is actively inhibited by IL-2. One
could have guessed that Th17 must
be less dependent on IL-2 because
one of the actions of TGF-b is to block
proliferation via its inhibitory action on
IL-2 (Brabletz et al., 1993). However,
Laurence et al. (2007) show that IL-2
is actively interfering with the differen-
tiation of Th17 T cells. Addition of ex-
ogenous IL-2 reduces the proportion
of Th17 in cultures of naive T cells
driven by TGF-b and IL-6, whereas278 Immunity 26, March 2007 ª2007 Elsinversely, blocking of endogenous,
autocrine IL-2 by the addition of neu-
tralizing antibodies enhances Th17
differentiation. Furthermore, IL-2-defi-
cient mice contain a substantially
greater fraction of Th17 T cells, and
in vitro stimulation of T cells from this
strain results in higher proportions of
IL-17-producing cells. Increased in-
duction of Th17 T cells under condi-
tions of IL-2 deficiency suggests that
some of the autoimmune disorder of
these mice may be due to the action
of Th17 T cells, a possibility that needs
to be explored further. A similar in-
crease in Th17 T cells was found
upon immunization of IL-2-deficient,
Rag-deficient T cell receptor-trans-
genicmice,which harbor amonoclonal
T cell population that is not activated
without deliberate immunization. Such
mice are not susceptible to the auto-
immune disorder seen in polyclonal
IL-2 deficient mice and the increased
proportion of Th17 T cells that devel-
oped after immunization with cognate
antigen are therefore unlikely to be
the direct result of an autoimmune
state.
The main rationale for assessing the
role of IL-2 in this paper was the re-
ported dichotomy of Th17 cell versus
regulatory T (Treg) cell differentiation.
The initial finding of a seemingly recip-
rocal activation of Treg versus Th17
cells was based on results showing
that in vitro stimulation of naive T cells
in the presence of TGF-b induces
Foxp3-expressing Treg cells, unless
IL-6 is added, in which case it supports
Th17 cell differentiation (Bettelli et al.,
2006). Although it remains dubious
whether such a pathway of Treg cellevier Inc.differentiation plays a significant role
under physiological conditions in vivo,
where T cell activation by antigen-pre-
senting dendritic cells is most likely
always accompanied by supply of
IL-6, there is no doubt that IL-2 plays
an obligatory role as a survival factor
for natural Treg cell generated in the
thymus. Thus, the study by Laurence
et al. (2007) provides an alternative
and possibly more physiologically
relevant example for Th17-Treg cell
dichotomy.
The mechanisms underlying the
blockade of Th17 differentiation by
IL-2 are not entirely clear, although
Laurence et al. (2007) offer a variety
of possibilities. STAT5, which is acti-
vated by IL-2 and other common g
chain (gc) cytokines, appears to be a
negative regulator of Th17 differentia-
tion in contrast to STAT3, which is
activated by both IL-6 and IL-23 and
positively regulates RORgt expression
and Th17 cell development (see Fig-
ure 1). STAT5-deficient mice harbor
an increased proportion of Th17 cells,
and in vitro polarization of thymocytes
(devoid of prepolarized Th17 cells)
results in enhanced Th17 differentia-
tion. The addition of IL-2 to cultures
of naive T cells under Th17-polarizing
conditions reduced the expression of
RORgt, and this paralleled the de-
crease in Th17 cell development. Thus,
despite the fact that STAT5-deficient
T cells seem to produce 10-fold more
IL-2 than T cells from wild-type mice,
as shown in a previous paper by this
group (Villarino et al., 2007), the ab-
sence of STAT5 precludes an inhibi-
tory effect on Th17 development.
Furthermore, Laurence et al. (2007)
Immunity
PreviewsFigure 1. The Differentiation of Effector CD4+ T Cells Is Shaped by Distinct
Cytokines, STAT Proteins, and Transcription Factors
Differentiation of Th17 cells is positively influenced by IL-6 and TGF-b, and STAT3 activation
results in upregulation of the lineage-defining transcription factor RORgt. In contrast, the Th1
cell lineage is driven by IL-12-STAT4, IFN-g-STAT1 pathways and the T-bet transcription factor.
The Th2 lineage is dependent on IL-4, STAT6, and the GATA-3 transcription factor. IL-2 (exocrine
or autocrine) positively regulates Th1 and Th2 cells but inhibits Th17 cell differentiation via acti-
vation of STAT5 and downregulation of RORgt.identified STAT5-binding sites in the
IL-17 promoter and suggest that
STAT5 might attenuate IL-17 produc-
tion by direct binding to the IL-17 pro-
moter. This, however, is not the same
as inhibiting Th17 cell differentiation.
IL-17 has no positive feedback effect
on the generation of the Th17 lineage,
and merely inhibiting cytokine produc-
tion would therefore not block their dif-
ferentiation. In contrast, it is not known
whether STAT5-mediated effects in-
fluence the amounts of IL-17 produced
by fully differentiated Th17 cells. This
study shows increased amounts of
IL-17 in the serum of STAT5-deficient
mice, which is presumably due to
increased Th17 development in such
mice. However, the possibility that
STAT5 signaling via IL-2 might reduce
IL-17 production by established Th17
effector cells was not explored but
might be of relevance in autoimmunitywhere the amounts of IL-17may deter-
mine the degree of pathology.
Laurence et al. (2007) clearly estab-
lish the negative role of IL-2 signaling
for Th17 cell development, an impor-
tant contribution that may hopefully
resolve residual difficulties still experi-
enced in attempts to generate Th17
cells in vitro. This applies especially
to the human system, where doubts
are circulating whether human Th17
development follows the same rule
as that of mouse Th17 development.
However, what remains unclear is the
physiological context in vivo in which
the IL-2-mediated Treg versus Th17
paradigm is applicable. The coculture
of Treg and naive T cells under con-
ditions that mimic an inflammatory
stimulus, e.g., in the presence of IL-6,
strongly supports Th17 generation
(Veldhoen et al., 2006). Given the po-
tential problem that Th17 cells couldImmunitycause autoimmunity, such a scenario
is clearly undesirable in vivo. Presum-
ably, Treg cells are not in the vicinity
when a T cell response is initiated by
contact with antigen presenting den-
dritic cells. However, Treg cells are no-
torious for scavenging IL-2 from re-
sponder cells and inhibiting their IL-2
transcription (Barthlott et al., 2005;
Thornton and Shevach, 1998), a sce-
nario that would seem ideal for the dif-
ferentiation toward the Th17 program.
Thus, although Treg clearly dampen
Th1- or Th2-mediated pathology, we
are left with the tantalizing question
of whether Treg cells, rather than con-
trolling Th17 cells, actually promote
Th17 development as well as their
effector function by scavenging their
negative regulator IL-2.
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